Anti-IL-20 monoclonal antibody alleviates inflammation in oral cancer and suppresses tumor growth
Menée in vitro et in vivo, cette étude suggère l'intérêt d'un traitement à base d'anticorps monoclonaux anti IL-20 pour les patients atteints d'un cancer de la cavité buccale
IL-20 is a proinflammatory cytokine involved in rheumatoid arthritis, atherosclerosis, and osteoporosis. However, little is known about the role of IL-20 in oral cancer. We explored the function of IL-20 in the tumor progression of oral cancer. IL-20 expression levels in tumorous and non-tumorous oral tissue specimens from 40 patients with four different stages oral cancer were analyzed with IHC staining and RTQ-PCR. Expression of IL-20 and its receptor subunits was higher in clinical oral tumor tissue than in non-tumorous oral tissue. The role of IL-20 was examined in two oral cancer cell lines (OC-3 and OEC-M1). In vitro, IL-20 promoted TNF-α, IL-1β, MCP-1, CCR4, and CXCR4, and increased proliferation, migration, ROS production, and colony formation of oral cancer cells via activated STAT3 and AKT/JNK/ERK signals. To evaluate the therapeutic potential of anti-IL-20 monoclonal antibody 7E for treating oral cancer, an ex vivo tumor growth model was used. In vivo, 7E reduced tumor growth and inflammation in oral cancer cells. In conclusion, IL-20 promoted oral tumor growth, migration, and tumor-associated inflammation. Therefore, IL-20 may be a novel target for treating oral cancer, and anti-IL-20 monoclonal antibody 7E may be a feasible therapeutic.